Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Solid Biosciences (SLDB) over the last 4 years, with Sep 2024 value amounting to $41.4 million.

  • Solid Biosciences' Shares Outstanding (Diluted Average) rose 106.60% to $41.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $41.4 million, marking a year-over-year increase of 106.60%. This contributed to the annual value of $19.9 million for FY2023, which is 133.60% up from last year.
  • Per Solid Biosciences' latest filing, its Shares Outstanding (Diluted Average) stood at $41.4 million for Q3 2024, which was up 1.24% from $40.9 million recorded in Q2 2024.
  • Solid Biosciences' Shares Outstanding (Diluted Average)'s 5-year high stood at $112.3 million during Q2 2021, with a 5-year trough of $3.5 million in Q4 2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $21.0 million, with a median of $19.7 million in 2023.
  • In the last 5 years, Solid Biosciences' Shares Outstanding (Diluted Average) crashed by 93.30% in 2022 and then surged by 166.30% in 2023.
  • Solid Biosciences' Shares Outstanding (Diluted Average) (Quarterly) stood at $3.5 million in 2020, then soared by 105.58% to $7.1 million in 2021, then rose by 19.58% to $8.5 million in 2022, then spiked by 133.60% to $19.9 million in 2023, then spiked by 106.60% to $41.4 million in 2024.
  • Its last three reported values are $41.4 million in Q3 2024, $40.9 million for Q2 2024, and $38.2 million during Q1 2024.